| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.073 | 0.3 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | -0.046 | 0.3 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.045 | 0.3 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | 0.029 | 0.3 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | Tipifarnib | FIMM | pan-cancer | AAC | 0.13 | 0.3 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.3 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |